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Aim. Vitiligo is an acquired hypomelanotic disorder characterized by circumscribed 
depigmented maculae on the skin. Current treatment procedures include narrow band 
UVB therapy, topical corticosteroids and imunomodulators. Aim of our study was to 
evaluate the efficacy and safety of topical tacrolimus in the treatment of vitiligo. 
Methods. Sixty patients (44 females, 22 males) with stable vitiligo were enrolled in 
our study. They did not show any benefits from topical corticosteroids, PUVA and 
NB-UVB therapy, so they were administered topical tacrolimus 0.1% twice a day and 
followed-up for 9 months. Results. At least a partial repigmentation was noticed with 
tacrolimus ointment in 46 patients after 9 months of therapy. Twenty-three of them 
obtained a good repigmentation, already evaluable at 3 months from the beginning of 
therapy and remaining the same at 6 and 9 months, respectively. The other 23 
patients obtained an excellent repigmentation, evaluable only at 9 months from the 
beginning of therapy, while a poor repigmentation was observed at 3 and 6 months. 
Two patients discontinued therapy because of side effects, while the remaining 12 
had no repigmentation at all. Conclusion. Topical tacrolimus could be considered an 
effective and safe therapy for vitiligo, expecially for patients who had no benefits 
from corticosteroids and/or phototherapy. 
